L'intérêt à découvert pour Tuya donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Tuya. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Tuya (NYSE:TUYA) Stock, Rapport sur les intérêts à découvert

Tuya

Tuya Inc is an IoT cloud development platform with a mission to build an IoT developer ecosystem and enable everything to be smart. The Company has pioneered a purpose-built IoT cloud development platform that delivers a full suite of offerings, including platform-as-a-service (PaaS) and Software-as-a-service (SaaS), to businesses and developers. Through its IoT cloud development platform, it has enabled developers to activate a vibrant IoT ecosystem of brands, OEMs, partners, and end users to engage and communicate through a broad range of smart devices. The company's revenue is derived from the PRC.

Tuya Inc. American Depositary Shares, each representing one Class A Ordinary Share

Tuya Inc

On June 28, 2025, ACM Research (Shanghai), Inc. ("ACM Shanghai"), the operating subsidiary of ACM Research, Inc. ("ACM"), announced that it received registration approval from the China Securities Regulatory Commission (the "CSRC") for its proposed private offering of ordinary shares to qualified buyers (the "Private Offering").
The approval permits ACM Shanghai to proceed with the Private Offering within 12 months from the date of approval. As previously disclosed by ACM on January 25, 2024, the proposed Private Offering is for up to 10% of ACM Shanghai's share capital prior to the offering. Based on ACM Shanghai's latest share capital, the number of shares to be offered has been updated to reflect the recent exercise of employee stock options. The Private Offering now provides for the issuance of up to 44.1 million ordinary shares, with expected gross proceeds of up to RMB 4.5 billion (approximately $625 million).

News

Offerings

ACMR

ACM Research Shanghai Receives CSRC Approval For Up To ~$625M Private Share Offering Within 12 Months

Biotech

General

GANX

Gain Therapeutics Completes Target Enrollment In Phase 1b Clinical Study Evaluating GT-02287 In People With Parkinson's Disease With Or Without GBA1 Mutation

Closes $2 Billion of First Lien Notes Due 2033
As part of an ongoing financial strategy to strengthen its capital structure and accelerate its transformation into a leading digital network services company, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lumen.com%2Fen-us%2Fhome.html%3Fgclsrc%3Daw.ds%26%26Creativeid%3Dbe93bb9f-d362-4050-95a7-0b5a32791816%26utm_source%3Dgoogle%26utm_medium%3Dcpc%26utm_campaign%3DNA_US_English_Paid%2BSearch_AdWords_Brand_Core_DG_Text_BCS_71700000072519948%26utm_content%3DLumen_Exact%26utm_term%3Dlumen%2520technologies%26gad_source%3D1%26gad_campaignid%3D10711850296%26gbraid%3D0AAAAACRBFV5wx9c5-hLEwFY6qrXOaNvE1%26gclid%3DEAIaIQobChMIluamzaCKjgMVsBitBh0nbxy2EAAYAiAAEgKEVvD_BwE&amp;esheet=54283429&amp;newsitemid=20250630733068&amp;lan=en-US&amp;anchor=Lumen+Technologies%2C+Inc&amp;index=1&amp;md5=6bb78e8146432a6eabbf327865e44020">Lumen Technologies, Inc</a>. ("Lumen", "us," "we" or "our") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) today announced that its wholly-owned subsidiary, Level 3 Financing, Inc. ("Level 3 Financing"), has closed its previously announced offering of $2.0 billion aggregate principal amount of 6.875% First Lien Notes due 2033 (the "First Lien Notes"). The First Lien Notes have a maturity date of June 30, 2033, and are guaranteed and secured on a first lien basis by Level 3 Parent, LLC, the direct parent of Level 3 Financing, and certain unregulated subsidiaries of the Issuer. Level 3 Financing used the net proceeds from the offering, together with cash on hand, to redeem all $924.522 million aggregate principal amount of Level 3 Financing's first lien 10.500% Senior Secured Notes due 2030 and all $667.711 million aggregate principal amount of Level 3 Financing's 10.500% First Lien Notes due 2029, and to partially redeem $166.565 million aggregate principal amount of Level 3 Financing's 11.000% First Lien Notes due 2029, in each case, including payment of redemption premium, and to pay related fees and expenses.

Financing

LUMN

Lumen Closes $2B First Lien Notes Offering Due 2033 To Strengthen Capital Structure And Redeem High-Interest Debt

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors
Company will also develop a subcutaneous version, PN-477sc, as a once-weekly injection
IND-enabling studies underway, with Phase I study initiation expected in 2Q26
Webcast and conference call to be held today at 4:30 pm ET
NEWARK, CALIFORNIA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 30, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-477, a potential best-in-class GLP-1, GIP, GCG receptor triple agonist peptide with oral and subcutaneous routes of administration, as a development candidate for the treatment of obesity. The triple agonist PN-477 is designed to offer the optimal combination of total body weight loss, improved gastrointestinal (GI) tolerability and fat to lean mass ratio, with the dosing convenience of a once-daily oral agent and the added optionality of a once-weekly subcutaneous administration.

PTGX

Protagonist Therapeutics Announces Selection Of PN-477, GLP-1, GIP, GCG Receptor Triple Agonist Peptide With Oral And Subcutaneous Routes Of Administration, As Development Candidate For Obesity Treatment

The Oncology Institute, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) ("TOI"), one of the largest value-based oncology groups in the United States, announced today that effective July 1, it will be the exclusive oncology provider for over 80,000 Medicaid patients associated with SilverSummit Healthplan in Nevada. TOI is known for bringing state-of-the-art cancer care to the communities it serves, and their presence in the Las Vegas market will provide enhanced access to care and high-level services to the important Medicaid population here.

The Oncology Institute Named Exclusive Oncology Provider For 80K SilverSummit Medicaid Patients In Nevada Starting July 1, 2025

Dyne Therapeutics Announces Proposed Public Offering Of $200M Common Stock

- SB Financial Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFG#NASDAQ">SBFG</a>) ("SB Financial"), a diversified financial services company providing full-service community banking, mortgage banking, wealth management, private client and title insurance services, today announced that it has been named to the Russell 3000&#xAE; and Russell 2000&#xAE;&nbsp;indices.
The annual reconstitution of the Russell US indices captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000&#xAE; Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000&#xAE; Index or small-cap Russell 2000&#xAE; Index as well as the appropriate growth and value style indices. FTSE Russell determines membership for its Russell indices primarily by objective, market-capitalization rankings and style attributes.

SBFG

SB Financial Group Announces It Has Been Named To The Russell 3000 And Russell 2000 Indices

SMCI

Super Micro Computer Intel Certification For BigTwin Multi-Node Server With 5th Gen Intel Xeon Scalable Processors

NBIX

Neurocrine Biosciences Reveals Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, A Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist

HALO

Halozyme Therapeutics Added To U.S. Large-Cap Russell 1000 Index

Olin And K2 Pure Solutions Expand Strategic Partnership To Strengthen Bleach Distribution Across California And Broader Western United States

NGNE

Neurogene Announces Written Agreement From FDA To Evaluate NGN-401 In Females With Rett Syndrome Ages 3 Years And Older Based On Natural History Study Analysis; Registrational Trial Initiation Activities Underway; Phase 1/2 Trial Fully Enrolled Showing No Evidence Of HLH/Hyperinflammatory Syndrome At 1E15 Vg Dose; Cash Runway Extended Into Early 2028

Management

Boeing Announces Jesus "Jay" Malave Has Been Elected As Incoming EVP And CFO, Effective Aug. 15

FrontView REIT Appoints Pierre Revol As CFO, Effective July 21, 2025

PRGS

Progress Software Acquires Nuclia; Size Not Disclosed, Says Is Immaterial To Financials

FRAME study demonstrated a 42.3% ORR and 20.1 months median PFS for all patients with low-grade serous ovarian cancer (LGSOC), regardless of KRAS mutation; for patients with KRAS-mutated LGSOC, ORR and mPFS were 58.3% and 30.8 months, respectively
Study conducted by the Institute of Cancer Research and The Royal Marsden NHS Foundation Trust demonstrated the importance of the intermittent dosing schedule of the combination of avutometinib and defactinib to improve tolerability and anti-tumor activity
Verastem Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that updated results from the Phase 1/2 FRAME study conducted by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust were published <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-025-03763-y&amp;esheet=54284274&amp;newsitemid=20250630352590&amp;lan=en-US&amp;anchor=online&amp;index=1&amp;md5=c8c6436bdaf119a55fb28a2d754f2661">online</a> in Nature Medicine. The full manuscript, titled "Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial," was the first-in-human study to evaluate the safety, tolerability, and efficacy of avutometinib in combination with defactinib in patients with low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), and other solid tumor types.

VSTM

Verastem Oncology Announces Publication Of Updated Results From Phase 1/2 FRAME Study Conducted By The Institute Of Cancer Research, London, And The Royal Marsden NHS Foundation Trust, In Nature Medicine

NKTR

Nektar Therapeutics Announces Proposed Public Offering Of Common Stock, Size Not Disclosed

Quantum Corporation (the "Company") has determined that it is unable to file its Annual Report on Form 10-K (the "Form 10-K") for the fiscal year ended March 31, 2025 ("Fiscal 2025") by&nbsp;June 30, 2025, the original due date for such filing, without unreasonable effort or expense due to the circumstances described below.
The Company is reviewing its accounting related to certain revenue contracts as well as the application of standalone selling price under applicable accounting standards. The results of the review will need to be reflected in the Company's financial statements for Fiscal 2025 in the Form 10-K. The Company does not expect the current review will affect the Company's financial statements for any fiscal periods prior to Fiscal 2025.
As a result, the Company has been unable to complete its consolidated audited financial statement close process for Fiscal 2025, and therefore unable to compile in a timely manner, without unreasonable effort or expense, the consolidated financial information required to prepare the Form 10-K for Fiscal 2025, within the prescribed time period.

Earnings

QMCO

Quantum Delays FY25 10-K Filing Due To Ongoing Review Of Revenue Accounting And Standalone Selling Price Application

HTGC

Dyne Therapeutics Enters $275M Debt Financing With Hercules Capital; $100M Upfront, $175M Tied To Milestones

Monotherapy efficacy and safety profile provided backbone for clinical development strategy&nbsp;in 1L combination with nivolumab plus chemotherapy
ROCKVILLE, MD, June 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced publication of the first-in-human monotherapy data for givastomig, a bispecific Claudin 18.2 x 4-1BB antibody, in Clinical Cancer Research, a journal of the American Association for Cancer Research (CCR), and a highly-ranked clinical oncology publication. The CCR paper1 details promising clinical data showing that givastomig monotherapy achieved an objective response rate (ORR) of 16% in heavily pretreated Claudin 18.2-positive gastric cancer patients. The publication can be accessed <a href="https://www.globenewswire.com/Tracker?data=FDx2tbcT6tXpL3oVUmEy71VpHWGi3USKCDuVNteEGk_88mOTZmmeYI6aQZu2vdnwNd54Fj4e3dk-UTrf3gLiFd4d4BUeIZKoVpA6OMUO_56TwIuyC9nxVQ3XV0JPCi6hydaNeS3oEVLar9D7t-MzeFvNVMNdX6KMdqoCiL50NBkHVgIzgLiDGJgBMwsuINim3FhJnWAz2nBSgoVL9knumGXIQpBNF9PbQnVbcvGvxig=">HERE</a>.
The CCR paper represents the first peer-reviewed manuscript publication of the Phase 1 monotherapy study of givastomig in heavily pre-treated solid tumor patients, after initial presentation of these data in poster form at the European Society of Medical Oncology (ESMO) Congresses in 2023 and 2024. The study evaluated a total of 75 patients with gastric cancers or other solid tumors, including 43 efficacy-evaluable patients with CLDN18.2-positive advanced or metastatic gastroesophageal carcinoma (GEC). Claudin 18.2 expression in responders ranged from 11% to 100%, demonstrating the activity of givastomig in tumors with low levels of Claudin 18.2 (CLDN18.2) expression. After the data cutoff, two additional patients were enrolled in the monotherapy study, resulting in an additional confirmed partial response (PR), leading to an increased ORR of 18% (8/45 patients). The Company anticipates sharing an updated monotherapy data set on the 45 patients in the fourth quarter of 2025 at a major medical meeting.
Monotherapy data indicate that givastomig is well tolerated and demonstrates single-agent activity in heavily pretreated patients. These findings support its development in combination with standard immunochemotherapy (nivolumab plus mFOLFOX6) as a first line (1L) treatment for gastric cancers. Data from the ongoing dose escalation combination study will be presented at a Mini Oral presentation at the ESMO Gastrointestinal (ESMO GI) Cancers Congress 2025 on July 2, 2025 in Barcelona, Spain.

IMAB

I-Mab Publishes First-in-Human Data For Givastomig Monotherapy In 'Clinical Cancer Research', Showing Up To 18% Response Rate In Heavily Pretreated Gastric Cancer Patients; Safety And Efficacy Support Ongoing 1L Combination Trials With Nivolumab And Chemotherapy

Press Releases

Tuya Smart's AI Large Model Provides the Optimal Solution Globally for Smart Energy Management

The Emotional Evolution of the Intelligent Era: Tuya Smart and DeepSeek Lead the Future of AI-driven Companionship

Tuya Smart Unveils Four Core AIoT Technology Engines, Empowering Developers to Reconstruct the Physical World with AI

Tuya Filed 2024 Annual Report on Form 20-F and Released Environmental, Social and Governance Report

Tuya to Report First Quarter 2025 Financial Results on May 20, 2025 Eastern Time

Tuya Upgraded to 'AA' ESG Rating by MSCI

Tuya Inc. to Hold Annual General Meeting on June 19, 2025

Tuya Reports First Quarter 2025 Unaudited Financial Results

Tuya Smart Secures Prestigious Spot Among "2025 Forbes China AI Tech Enterprises Top 50"

Comments

Tuya

Intérêt court

Tuya (NYSE:TUYA) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL